SEARCH: Short Message Service 
(SMS) Electronic Adolescent 
Reminders for Completion of HPV 
Vaccination - Uganda: Pi[INVESTIGATOR_315767].gov ID: [STUDY_ID_REMOVED]
Document date:  August 9, 2021
COLLEGE  OF HEALTH  SCIENCES  
DEPARTMENT  OF PAEDIATRICS  AND CHILD  HEALTH  
SEARCH:  SMS  Electronic  Adolescent  Reminders  for Completion  of 
HPV  vaccination  in Uganda  
PRINCIPAL  INVESTIGATOR:  
[CONTACT_91511]. SABRINA BAKEERA -KITAKA  (MBChB,  MMed  Paed,  PhD)  
CO-INVESTIGATORS:  
1.DR. MELISSA  STOCKWELL  (MD MPH)
2.DR. BETSY  PFEFFER  (MD)
3.DR. JOSEPH  RUJUMBA  (SWSA,  MA,  PhD)
4.DR. SARAH  ZALWANGO  (MBChB,  MPH)
5.DR. NICOLETTE  NAB[LOCATION_006]EERA -BARUNGI  (MBChB,  MMed,  PhD)
6.DR. JULIET  BABIRYE  (MD,  MPH,  PhD)
7.DR. EZEKIEL  MUPERE  (MBChB,  MMed,  MSc,  PhD)
8.DR. ASHLEY STEPHENS  (MD)
2021  

3.4.2 Objective 2b Study Populationâ€¦â€¦â€¦ 17 OPERATIONAL DEFINITIONâ€¦â€¦â€¦  
LIST OF ABBREVIATIONSâ€¦â€¦â€¦  
ABSTRACTâ€¦â€¦â€¦  
Backgroundâ€¦â€¦â€¦  
Objectivesâ€¦â€¦â€¦  
Methodsâ€¦â€¦â€¦  
Utilityâ€¦â€¦â€¦  
Anticipated Study Outcomesâ€¦â€¦â€¦ 
CHAPTER ONEâ€¦â€¦â€¦  
1.0 INTRODUCTIONâ€¦â€¦â€¦  1 
1.1 Backgroundâ€¦â€¦â€¦  1 
1.2 Problem Statementâ€¦â€¦â€¦  2 
1.3 Justificationâ€¦â€¦â€¦  2 
1.4 Research Questionâ€¦â€¦â€¦  2 
1.5 General Objectiveâ€¦â€¦â€¦  3 
1.5.1 Specific Objectivesâ€¦â€¦â€¦  3 
1.6  Conceptua l Frameworkâ€¦â€¦â€¦  3 
CHAPTER TWOâ€¦â€¦â€¦  
2.0 LITERATURE REVIEWâ€¦â€¦â€¦  4 
CHAPTER THREE  
3.0 METHODOLOGYâ€¦â€¦â€¦  10 
Study Schemaâ€¦â€¦â€¦  10 
Pi[INVESTIGATOR_315768]â€¦â€¦â€¦ 11 
3.1 Study designâ€¦â€¦â€¦  12 
3.2 Study Siteâ€¦â€¦â€¦  12 
3.3 Objective 1  13 
3.3.1 Study Populationâ€¦â€¦â€¦  13 
3.3.2 Selection Criteriaâ€¦â€¦â€¦  13 
3.3.3 Study Procedureâ€¦â€¦â€¦  14 
3.3.4 Data Management and Analysisâ€¦â€¦â€¦  16 
3.4 Objective 2  16 
3.4.1 Objective 2a Study Procedure  17 
Scaleâ€¦â€¦..  3.4.3 Objective 2b Selection Criteriaâ€¦â€¦â€¦  18 
3.4.4 Objective 2b Study Procedureâ€¦â€¦â€¦  18 
3.4.5 Data Management and Analysisâ€¦â€¦â€¦  19 
3.5 Objective 3  
3.5.1 Study Populationâ€¦â€¦â€¦  19 
3.5.2 Selection Criteriaâ€¦â€¦â€¦  19 
3.5.3 Study procedureâ€¦â€¦â€¦  19 
3.5.4 Data management and analysisâ€¦â€¦â€¦  23 
3.6 Training of Research Assistantsâ€¦â€¦â€¦  25 
3.7 Ethica l Considerationâ€¦â€¦â€¦  25 
3.8 Dissemination of Resultsâ€¦â€¦â€¦  26 
REFERENCESâ€¦â€¦â€¦  29 
Appendicesâ€¦â€¦â€¦  
Study Instruments  
   Objective 1  
Appendix 1: English Caregiver Interviewâ€¦â€¦â€¦  33 
Appendix 2: Luganda Caregiver Interviewâ€¦â€¦â€¦  37 
Appendix 3: English Adolescent Interviewâ€¦â€¦â€¦  41 
Appendix 4: Luganda Adolescent Interviewâ€¦â€¦â€¦  44 
Appendix 5: English Staff/Clinic Interviewâ€¦â€¦â€¦  47 
Appendix 6: Luganda Staff/Clinic Interviewâ€¦â€¦â€¦  49 
Appendix 7: Governmental Interviewâ€¦â€¦â€¦  52 
   Objective 2  
Appendix 8: Message Pre -Test Questions - Englishâ€¦â€¦â€¦  54 
Appendix 9: Message Pre -Test Questions - Lugandaâ€¦â€¦â€¦  58 
   Objective 3  
Appendix 10: English Demographic/HPV Knowledge 
     Surveyâ€¦â€¦..  62 
Appendix 11: Luganda Demographic/HPV Knowledge 
     Surveyâ€¦â€¦..  67 
Appendix 12: English Health IT Usability Evaluation 
Scaleâ€¦â€¦..  72 
Appendix 13: Luganda Health IT Usability Evaluation 
73 
Appendix 14: Acceptability of Intervention Measure (AIM) 
and Intervention Appropriateness Measure (IAM)â€¦â€¦..  74 
Appendix 15:  Luganda Acceptability of Intervention Measure  
    (AIM) and Intervention Appropriateness Measure (IAM)  75 
Appendix 16: English Post -Intervention Family  
Interviewâ€¦â€¦..  76 
Appendix 17: Luganda Post -Intervention Family 
Interviewâ€¦â€¦..  77 
Appendix 18: English  Post-Intervention Staff/Clinic 
Interviewâ€¦â€¦..  78 
Appendix 19: Luganda Post -Intervention Staff/Clinic 
Interviewâ€¦â€¦..  79 
Appendix 20: Post -Intervention Government Interviewâ€¦â€¦.80  
Consents  
    Objective 1  
Appendix 21: English Caregiver Information Sheet and 
Informed Consent Formâ€¦â€¦â€¦  81 
Appendix 22: Luganda Caregiver Information Sheet and 
Informed Consent Formâ€¦â€¦â€¦  84 
Appendix 23: English Adolescent Information Sheet and 
Informed Assent Formâ€¦â€¦â€¦  89 
Appendix 24: Luganda Adolescent Information Sheet and 
Informed Assent Formâ€¦â€¦â€¦  91 
Appendix 25: English Clinic Staff Information Sheet and 
Informed Consent Formâ€¦â€¦â€¦  94 
Appendix 26: Luganda Clinic Staff Information Sheet and 
Informed Consent Formâ€¦â€¦â€¦  97 
Appendix 27: Government Information Sheet and 
Informed Consent Fo rmâ€¦â€¦â€¦  101 
Objective 2  
Appendix 28:  English Caregiver Pre -Test Information  
Sheet and Consent Formâ€¦â€¦â€¦  104 
Appendix 29: Luganda Caregiver Pre -Test Information 
Sheet and Consent Form â€¦â€¦â€¦  107 
Biosketch â€¦â€¦â€¦  Appendix 30: English Adolescent Pre -Test Information  
Sheet and As sent Formâ€¦â€¦â€¦  112 
Appendix 31: Luganda Adolescent Pre -Test  Information 
Sheet and Assent Formâ€¦â€¦...  114 
Objective 3  
Appendix 32:  English Caregiver Intervention Information  
Sheet and Consent Formâ€¦â€¦â€¦  117 
Appendix 33: Luganda Caregiver Intervention Information 
Sheet and Consent Form â€¦â€¦â€¦  121 
Appendix 34: English Staff Post -Intervention Information  
Sheet and Consent Formâ€¦â€¦â€¦  125 
Appendix 35: Luganda Staff Post -Intervention Information 
Sheet and Consent Form â€¦â€¦...  128 
Appendix 36: Government Post -Intervention Information  
Sheet and Consent Formâ€¦â€¦...  131 
Letters of Support  
Appendix 37: KCCA Directorate of Public Health Support  
Letterâ€¦â€¦â€¦  
Appendix 38: KCCA Directorate of Education and Social  
Services Support L etterâ€¦â€¦â€¦  
Appendix 39: Ministry of Health Support Letterâ€¦â€¦â€¦  
Other Study Documents  
Appendix 40: COVID -19 Risk Management Planâ€¦â€¦â€¦  
Appendix 41: Proposed Budgetâ€¦â€¦â€¦  
Appendix 42: KCCA Affiliated Schoolsâ€¦â€¦â€¦  
Curriculum Vitaes  
Appendix 43: [CONTACT_315835] -Kitaka  
Biosketch â€¦â€¦â€¦  
Appendix 44: [CONTACT_315836]â€¦â€¦â€¦  
Appendix 45: [CONTACT_315837]â€¦â€¦â€¦  
Appendix 46: [CONTACT_315838]â€¦â€¦â€¦  
Appendix 47: [CONTACT_315839]â€¦â€¦â€¦  
Appendix 48: [CONTACT_315840] -Barungi  
Appendix 49: [CONTACT_315841]â€¦â€¦â€¦  
Appendix 50: [CONTACT_315842]â€¦â€¦â€¦  
Appendix 51: [CONTACT_315843]â€¦â€¦â€¦  
OPERATIONAL  DEFINITIONS  
Adolescence:  The period of  physical  and psychological  development  from the  onset  of puberty  
to adulthood.  
Adolescent:  A person of  age 10 â€“ 19 years.  
Vaccine:  is a suspension  of live (attenuated/weakened)  or inactivated  microorganisms  (e.g. 
bacteria,  viruses)  or fractions  of microorganism  administered  to induce  immunity and prevent  an 
infectious  disease or its complications.  
Vaccine  completion:  defined  as having  received  two doses  of the HPV  vaccine  series  with an 
interval  of [ADDRESS_388681] OF  ABBREVIATIONS  
HPV - Human  papi[INVESTIGATOR_315769]  - Kampala Capi[INVESTIGATOR_315770]  â€“ Uganda  National  Expanded  Programme  on Immunization  
[LOCATION_003] â€“ United  States  of America  
ABSTRACT  
Background - Cervical cancer is the leading female cancer in Uganda. HPV is the principal cause 
of cervical cancer, making vaccination the single most important primary preventive measure. 
However, in Kampala, Uganda only 29% of girls receive both needed doses. Reasons  for under -
vaccination include school absenteeism on special vaccination days, failing to remember to come 
to a health facility for a needed dose, and lack of knowledge regarding HPV and the vaccines. 
While research regarding the use of text message has no t yet been demonstrated in a 
preteen/adolescent population in sub -Saharan African or other low - and middle -income countries 
(LMICs), phone reminders may improve adherence to vaccination completion rates. According to 
the World Bank, 89.9% of urban househol ds in Uganda have a cell phone. While text messages 
can be used in populations with low literacy, families can opt to receive automated phone call 
reminders instead.  
Objectives - This protocol is for text and voice phone message intervention development fo r a 
subsequent pi[INVESTIGATOR_315771].  The specific objectives are as follows:  
1)To identify HPV vaccine text message reminder content (and parallel automated voice
phone reminders) d esired by [CONTACT_315809].
2)To develop and pre -test HPV vaccine reminders with caregivers and their adolescent girls
in Kampala.
3)To pi[INVESTIGATOR_315772] - This study will utilize a qualitative approach as part of an exploratory sequential design 
with the primary intent of the exploratory design is to develop a digital tool which will then be 
tested.  We will conduct formative research using key infor mant interviews with families of 
preteen/ adolescent girls  (throughout will be called adolescent)  (n=30 dyads/triads), clinicians and 
immunization nurses of involved study sites (n=10), administrative staff and school leadership of 
involved study sites (n=12), and leadership within the KCCA and Ministry of Health (n=4)  to 
assess attitudes towards HPV vaccination and text message reminders. Using the results from the 
interviews we will create prototypes of messages that will be shared with families (n=30 dyads) to 
identify issues with clarity, tone, and persuasiveness. Next, we will conduct a pi[INVESTIGATOR_201834] l to 
randomize caregivers of adolescents at one KCCA site and the adolescent clinic, stratified by [CONTACT_3725], 
language and HPV vaccine dose needed (initiation vs. completion). Feasibility milestones will 
include reach, effect size determination and implementati on measures. If the pi[INVESTIGATOR_315773], we 
will conduct a future full -scale RCT assessing the impact of the HPV vaccine text message 
reminders. The main outcome will be timeliness of vaccination. We will also collect 
process/feasibility measures.  
Utility o f the Study  - The messages will be used for a pi[INVESTIGATOR_315774].  
Anticipated Study Outcomes - This study will allow us to understand the types of educational 
information paren ts and providers believe is needed in HPV vaccination reminders in an LMIC. 
We will be able to use this information in a future large -scale intervention that will utilize text 
message reminders to prompt caregivers to return their adolescents for their nex t HPV dose.  
3DJHRI&+$37(521( 
 ,1752'8&7,21 
 %DFNJURXQG 
&HUYLFDO&DQFHUUDWHVLQ8JDQGDDUHKLJK 6XE6DKDUDQ$IULFDRYHUDOO KDVWKHKLJKHVWFHUYLFDO
FDQFHUPRUWDOLW\UDWHVLQWKHZRUOG)LJ&HUYLFDOFDQFHULVWKH OHDGLQJFDQFHUDPRQJZRPHQ
LQ8JDQGD7KHUHDUHQHZ FDVHVGLDJQR VHGDQGGHDWKV DQQXDOO\DQGWKDWQXPEHULV
ULVLQJQHDUO\GRXEOLQJVLQFH8SWRRIZRPHQDUHGLDJQR VHGZLWKODWHVWDJHGLVHDVH
DQGGLHZLWKLQ\HDUVRIGLDJQRVLV7KHDJHVWDQGDUGL]HGFHUYL FDOFDQFHULQFLGHQFHUDWHLQ
8JDQGDRIZ RPHQSHU\HDULV RYHUWLPHV WKDWRIWKHUHVWRIWKHZRUOG7KHDJH
VWDQGDUGL]HGPRUWDOLW\UDWHRIZRPHQLVQHDUO\ WLPHV+39LVWKHSULQFLSDOFDXVH
RIFHUYLFDOFDQFHUDQGRI LQYDVLYHFHUYLFDOFDQFHUVDUHD WWULEXWHGWR+39VWUDLQVRU
+39SRLQWSUHYDOHQFHLQQRUPDO FHUYLFDOF\WRORJ\LQ8JDQGDUDQJ HVIURP
)LJ$JHVWDQGDUGL]HGPRUWDOLW\UDWHVRI FHUYLFDOFDQFHULQWKH:RUOG
+399DFFLQDWLRQLVWKHVLQJO HPRVWLPSRUWDQWSULP DU\SUHYHQWLYH PHDVXUHIRU+39 ,QLWLDO
FOLQLFDOWULDOVRI+39YDF FLQDWLRQDPRQJ\RXQJZRPHQLQ FRXQWULHVVKRZHGQHDU
HIILFDF\LQULVNUHGXFWLRQLQ W\SHVSHFLILFFHUYLFDOYXOYD UDQGYDJLQDOFDQ FHUVFHUYLFDO
G\VSODVLDDQGJHQLWDOZDUWV$V\VWHPDWLFUHYLHZRI+ 39YDFFLQHSURJUDPVDFURVV
FRXQWULHVRYHUWHQ\HDUVIRXQGD SSUR[LPDWHPD[LPDOUHGXFWLRQVR IIRU+39
VWUDLQLQIHFWLRQIRUJHQLWDO ZDUWVIRUORZJUDGHDQG IRUKLJKJUDGHF\WRORJLFDO

Page  2 of 142 cervical  abnormalities.13  HPV also  plays  an important role in anal,  vulvar,  penile and  
oropharyngeal  cancer.1 
1.2 Problem  statement:  
An important  public  health  goal is enhancing  HPV  disease  prevention  through  HPV  vaccination.  
Despi[INVESTIGATOR_315775].  Uganda  rolled  out the HPV  
vaccination  into the  national extended  programme  on immunization (UNEPI)  in November 2015.  
However,  of the adolescents  who receive  the first dose of HPV  vaccine  many  do not receive  the 
second  dose they need  to complete  the series  for adequate  protection.  Furthermore,  of those  who 
do receive  the second  dose,  many  do not receive  it in a timely  fashion  within  the recommended  12 
months,  resulting  in more  days at risk. In two previous  national  surveys,  72% and 83% of girls 
assessed  initiated  vaccination, but only  39% and 27% of them,  respectively,  completed  the series.  
1.3 Justification:  
Text messages  could  be used to address  many  of the problems  identified  with poor HPV  vaccine  
uptake.  The study  assessing  HPV  demonstration  projects  in LMICs  found  main  vaccination  
barriers  to include:  1) school  absences  on vaccination  days and 2) lack of knowledge  or awareness  
about  cervical  cancer,  HPV  vaccine  and HPV  vaccination  programs.  All these,  and more,  are 
targetable with  HPV vaccine  text message  reminders.  
Although  there  is evidence  from  developed  countries  that text messaging  is an effective  
intervention  to promote  vaccine  completion  rates,  there  is a knowledge  gap about  its use in 
resource -limited  settings.  Since  the rates of mobile  phone  possession  is high in this population,  it 
is important  to test the effectiveness  of vaccine reminder  text messages.  
1.4 Research Questions  
What message content would key stakeholders prefer for HPV vaccination reminders?  
Are text message vaccine reminders for HPV vaccination feasible?  
Do text message vaccine reminders demonstrate potential impact on timely HPV vaccination 
initiation and completion?  
3DJHRI*HQHUDO2EMHFWLYH
7RH[SORUHDWWLWXGHVRINH\VWDNHKROGHUV DGROHVFHQWVFDUHJLYH UVKHDOWKZRUNHUVDQGVFKRRO
DXWKRULWLHVWRZDUGV+39YDFFLQDWLRQDQGWH[WPHVVDJHUHPLQGHUV LQ.DPSDODDQGWRXVHWKRVH
PHVVDJHVLQDSLORWUDQGR PL]HGFRQWUROWULDOWRDVHVVVWKHIHDV LELOLW\RIWH[WPHVVDJHUHPLQGHUVRQ
+39YDFFLQDWLRQ
6SHFLILF2EMHFWLYHV
7RLGHQWLI\+39YDFFLQHWH[WPHVVDJHUHP LQGHUFRQWHQWDQGSDUDOOH ODXWRPDWHGSKRQH
UHPLQGHUVGHVLUHGE\ WKHFDUHJLYHUVDQGWKHLUDGROHVFHQWJLUOV LQ.DPSDOD
7RGHYHORSDQGSUHWHVW+39YDFFLQHUH PLQGHUVZLWKFDUHJLYHUVDQG WKHLUDGROHVFHQWJLUOVLQ
.DPSDOD
7RSLORWDVVHVVWKHLPSDFW DQGIHDVLELOLW\RIYDFFLQHUHPLQGHUV RQ+39YDFFLQDWLRQ
 &RQFHSWXDO)UDPHZRUN
7RXQGHUVWDQGWKHGHWHUPLQDQWVLQIOXHQFLQJ+39YDFFLQDWLRQZHZ LOOJURXQGRXUDQDO\VLVLQWKH
JHQHUDOGRPDLQVRIWKHFULWLFD OLQWHUSUHWLYHV\QWKHVLVIUDPHZRU NSXWIRUWKE\3KLOOLSVHWDOLQWKHLU
FRPSUHKHQVLYHV\VWHPDWLFUHYLHZRIYDFFLQDWLRQVWXGLHVLQ/0,&V )LJXUH7KLVZLOOEHXVHGWR
DQDO\]HLQWHUYLHZVZLWKFDUHJLYHUV DGROHVFHQWVFOLQLFDOVWDII KHDGPDVWHUVDQGVFKRROVWDIIDQG
JRYHUQPHQWZRUNHUVWRLQIRUPPHVVDJHFRQWHQWDQGXQGHUVWDQGWKH EDUULHUVDQGIDFLOLWDWRUVWR+39
YDFFLQDWLRQLQ.DPSDOD
)LJ&RQFHSWXDOIUDPHZRUNIRUYDFFLQHFRYHUDJHLQ/0,& 3KLOOLSV'(HWDO' HWHUPLQDQWVRI
HIIHFWLYHYDFFLQH  FRYHUDJHLQORZDQGPLGGOHLQFRPHFRXQWULHVDV\VWHPDWLFUHYL HZDQGLQWHUSUHWLYHV\QWKHVLV
%0&+HDOWK6HUY5HV 

Page  [ADDRESS_388682] dose of HPV  vaccine receive  the second  dose they need 
to complete the series.  Furthermore,  of those  who do receive the second dose, many  do not  
receive it within  the recommended  12 months, resulting  in more days  at risk. In two previous  
national  surveys,  72% and 83%  of girls assessed  initiated vaccination,  but only 39% and 27% of 
them,  respectivel y, completed  the series.[ADDRESS_388683] gone  up in some  areas  of 
Uganda,  in Kampala City currently  only 29% of girls in the  target  age range  have received  two 
doses  of the vaccine.17 Similarly,  at an adolescent  clinic ( study site) in Kampala,  of the girls aged  
less than 14 years  old who initiated  vaccination  between  November 2015 and July 2017, only 
30.2%  completed  the series  within  6 months and 36.5%  within  12 months â€”and only 69.8%  
completed  the series  at all.18 At three local  health  centres  and affiliated  schools (study sites ), 
average completion  rates are even lower,  ranging  from  10.5%  to 40.5%  of those  who initiated.17 
The current  rate of completion HPV2  is 12% .[ADDRESS_388684]  at boarding  school when  
the next dose  is due; when  they return  from school  break,  the family  may not remember to return  
Page  [ADDRESS_388685] knowledge  gaps regarding  the link 
between  HPV  and cervical  cancer as  well as misperceptions  regarding  the vaccine.  In one study  
that included  stakeholder  interviews,  investigators  found  that a key driver  of vaccination  was 
fears  about  vaccine safety.2 Another showed that the perceived  benefits  of vaccination - 
particularly  cancer  protection as well as perceived  safety  of HPV vaccination - increased  girls'  
and caregivers'  acceptability  of HPV vaccination.[ADDRESS_388686] at  an 
adolescent  clinic (a site  for this study ), knowledge  about  cervical  cancer,  HPV, and HPV  
vaccination  were  associated with  increased  vaccine  coverage.  Other  investigators  have  also 
found  that families  chose  vaccination  because it protects  against  cervical  cancer,  prevents  
infection,  and because vaccines overall  are good  for health.[ADDRESS_388687], scalable opportunities  to foster  vaccination.  Traditional  
reminder strategies  (mail  and phone  call) have historically  had more limited  effects  in adolescent  
and low-income populati ons.26-[ADDRESS_388688]  size with high certainty  of evidence (RR:  1.29,  
95% CI: 1.15 â€“ 1.44; six  studies;  7,772 participants) .[ADDRESS_388689] several  characteristics  making  them  an attractive  
technology  for vaccine  reminders  in all populations.  
a)Text messages  are a good  way to reach  people . The number of mobile  phone  user is high,
with an estimated  6.8 billion users  world -wide.32 According  to the  World  Bank,  89.9%  of
urban  households  in Uganda have  a cell phone.33 
Page  6 of 142 b)Text messages  act as cues to  action.  They  may draw  attention  more than  written  information
and may be perceived  as less intrusive than  a phone  call.24 In addition,  they remain  on a
personâ€™s  phone  as a persistent  reminder.  This makes them  particularly  useful for
interventions  with a clear, desired  behavioral  outcome.
c)Text messages  are useful across  populations  with various  levels  of literacy  since space
limitations  force a minimal  number of short,  simple  words.
d)Text messages  are delivered  outside  the office setting . This is important  for reaching  patients
not accessing  care regularly,  a key group  for targeting  HPV vaccine reminders  as well as for
school -based  programs.  Text messages  also allow  more frequent  contact  [CONTACT_4490] a  health  care
team  than can be achieved with in -person  visits alone.
e)Text messaging  is scalable  and can be personalized . It allows  interaction  with thousands  of
patients  simultaneously  thereby  [CONTACT_315810]â€™ health,
but also on the  health  of the public  by [CONTACT_315811] -level  vaccination  coverage.  Yet,
text messaging  can also allow  personalization  based  on individual  characteristics  such as age
and language.
f)Text message reminders  are a flexible  platform. They  can be used either  for simple  prompts
or for reminders  that inform a  patient  or family  when a  vaccine is needed,  and even for more
complex  interactions  that include embedded  educational information  and interactive
responses  that can close  knowledge  gaps and dispel  vaccine misperceptions.
Text messages  could  be used to address  many  of the problems  identified  with poor  HPV vaccine  
uptake.  The study  assessing  HPV demonstration  projects  in LMICs  found  main  vaccination  
barriers  to include: 1)  school absences  on vaccination days and 2) lack of  knowledge  or 
awareness  about  cervical  cancer,  HPV vaccine  and HPV vaccination  programs. All these,  and 
more,  are targetable with  HPV vaccine text message  reminders.22 
ïƒ  They  can notify  famili es that their child  is in need of vaccination  either for their first  dose 
or that it is time  to return  for the second dose  
ïƒ  Timing  of reminders  can be tailored  to the  individual  child  based  on when  their dose is 
due as well as where  and when  they should  go to receive that dose,  including  special  days 
at school.  
Page  7 of 142 ïƒ  Educational  information  can be embedded  into text messages  to provide answers  to 
common  questions  or concerns  families  have about vaccination  or include  information  
that has been shown  to impact the  likelihood  of caregivers  to accept  vaccination, like  
cancer protection.  
We have established  strong evidence supporting HPV  vaccine text  message  reminders.  [CONTACT_315844]  (MPI  [INVESTIGATOR_40349]) published  the first studies  using  text message  vaccine  reminders  for 
adolescent  and pediatric  popula tions.34-[ADDRESS_388690] or  second  dose of the HPV vaccine  received  a series  of text message  
reminders  when the  next dose  was due. Adolescents whose caregivers  were  texted were more  
likely  to receive their next dose on -time vs. non-enrollees  (51.6% of enrollees  vs. 35.0%  of non- 
enrollees  [p = 0.001]  or 38.1%  of historical  controls [p=0.003]).40 In a secondary  analysis  
(unpublished),  those  receiving  text messages  also had higher series  completion rates (45% vs. 
29% p<0.01).  These  conventional  reminders  solely  notified  caregivers  via text that the next dose 
was due; they did not include  any other information  such as vaccination -related  educational  
health  information.  While these results strongly  supported the  potential  effectiveness  of text 
message reminders,  still fewer than  half of adolescents  (45%) completed  the series.  
In her most recent  study,  Stockwell  demonstrated  74.1%  completion  rates of HPV vaccine series  
within  12 months for adolescents  of caregivers  receiving  text message reminders.41 This rate was  
much  higher than  both historical  controls  (34.8%)  and the comparison  group  of non-enrollees  
(45.2%,  p<0.0001).  
This proposed  project  is innovative  in four important  ways.  
1)This will be the first use of text message vaccine  reminders  for adolescent  vaccinations
in not only  Africa but for any LMIC.  Text message vaccine reminders  have been used for
pediatric vaccination  studies in Africa in Kenya and Nigeria33,42-[ADDRESS_388691] of sub-Saharan  Africa,  vaccinations  for young
children  are delivered  as part of EPI (Expanded  Programme on Immunization) in
which  primarily  families  bring  their child  in to a  central  location  for vaccination.
This differs  from  vaccination for adolescents,  who are being  vaccinated  in a
variety  of places,  including  the school, health  centres  and immunization posts in
the community.  This means that a more tailored  mHealth  approach  is needed to be
able to provide reminders for these various groups.
b.Caregiver views of  pediatric vaccination  are generally  positive,  while in contrast
many  concerns  about  HPV  vaccination  still exist making  the embedded
educational  information  in HPV reminders  particularly  important.
c.Caregivers  are very accustomed to thinking  about  vaccinations  for their infants
but vaccinations  for adolescents  are much  newer to them  and knowledge  gaps
remain.50 In addition,  care seeking  patterns  for infants may  differ markedly  than
for adolescents,  making  this type of outreach  potentially  even more  important.
2)We will also be able to assess for the first time what  types  of educational  information
caregivers  and providers  believe is needed  in HPV vaccination  reminders  in a LMIC.  An
August  2018 article highlighted  that while nearly  a quarter  of the  worldâ€™s  population are
adolescents , on average  only 1.6%  of all global health  development  assistance funding
goes to adolescent  health .51 Given  the very high burden of  cervical  cancer  coupled  with
late diagnosis,  the opportunity  for primary  prevention offered  by [CONTACT_315812].
Uganda has  a young  population, 59.7%  are <[ADDRESS_388692]  may also be useful to other  LMICs.
3)This project  is at the intersection  of two important  governmental  ministries - the Ministry
of Health  and the Ministry  of Education - these  mHealth  reminders  would  be a novel
intervention  spanning  the two arenas  of health and education.
Page  [ADDRESS_388693]  and reverse  translated  into Luganda.  
Message  Pre-Testing  (N=20  dyads)  
Parenting  adult  with girl aged 10-14 years,  residents  of Kampala  or surrounding  districts,
affiliated with  one of the study  sites (care  or school),  speak  English  or Luganda will  pre-test
messages.  
Pi[INVESTIGATOR_315776]  
(N=154)  
Intervention Arm: Targeted reminder messages to initiate 1st or 2nd dose 
receipt  
Usual Care Arm: No reminder messages  
CHAPTER THREE  
3.0 METHODOLOGY  
Study  Schema  
(N=30 dyads/triads)  
Caregiver  with girl aged  10-14 years,  residents  
of Kampala  or surrounding  districts,  affiliated  
with one of the study  sites (care  or school),  
speak  English  or Luganda,  and have a cell 
phone  with text message  capability  (N=10)  
Immunization  
nurses,  
administrative  
staff,  and medical  
leadership  at 
health  
centers/clinics.  
(N= 12) 
and staff at
Child  Days
Plus
programs.  
(N=4)  
Kampala
Capi[INVESTIGATOR_315777] a RE -AIM 
implementation framework (Reach, Effectiveness, Adoption, Implementation, Maintenance). 
OBJECTIVE  1 OBJECTIVE  2 OBJECTIVE 3  
Page  11 of 142 
Pi[INVESTIGATOR_315778] (N=77 families)  
Targeted  reminder messages  to initiate 1st or 2nd
dose receipt  
USUAL  CARE (N=77  families)  
No reminder messages  
ELIGIBLE (N=913  families)  
Parenting  adult  must: have a girl aged 10-14 years,  be a 
resident  of Kampala or surrounding  districts,  be affiliated  
with one of the study  sites (care or school),  speaks  
English  or Luganda,  and have cell phone  with text 
message capability  
ENROLL (N=154  families)  
Consent  and enroll  in SEARCH Study  
RANDOMIZE  
by [CONTACT_315813], parental  language (English  or 
Luganda),  and dose due (1st or 2nd) 
Page  12 of 142 3.1 Study  Design  
This is an exploratory sequential design study with the primary intent of the exploratory design to 
develop a digital tool which will then be tested in a pi[INVESTIGATOR_315779]. This study will be conducted in Kampala City 
involving adolescent girls, their caregivers,  health workers, school authorities  and government 
officials . Results from this phase (Objective 1: interviews) will be used to design the text and 
voice message reminders. We will use these results, along with the study teamsâ€™ expertise in in text 
messaging, HPV vaccination, adolescent medicine, health literacy and community engagement 
(Objective 2: message design and pretest), for a pi[INVESTIGATOR_315780] (Objecive 3: pi[INVESTIGATOR_315781]).  
3.[ADDRESS_388694]  at three health centres  Kisenyi,  Kawaala and  Kiswa in Kampala,  
Uganda overseen  by [CONTACT_315814][INVESTIGATOR_315782]  (KCCA) located  in the suburbs  of 
Kampala City.  It will also take place  in a sample  of six KCCA schools  selected  from the  schools  
in those  areas  (Appendix  26). It will also take place  at the Makerere/Mulago/Columbia  
Adolescent  Health  Clinic  (commonly  referred  to as the  Friday  Adolescent  Clinic),  at Mulago  
National  Referral  Hospi[INVESTIGATOR_315783].  The study  health facilities  were selected  purposively  in consultation with KCCA to 
ensure inclusion  of different  city divisions as shown in Table 1. 
Table  1: Distribution  of study  health  facilities  by [CONTACT_315815]1
Kisenyi  HC IV Central  99,378  
Kiswa HC    III Nakawa  64,509  
Kawaala HC  III Lubaga  52,035  
Mulago  National  Referral  Hospi[INVESTIGATOR_307]  -Adolescent  Clinic  Kawempe  
1 KCCA  (2019) Statistical Abstract https:/ /www.kcca.go.ug/media/docs/Statistical -Abstract -2019.pdf
Each  of the study  health facilities  provides  HPV vaccination  services  to adolescent  girls.  
Page  13 of 142 3.3 Objective  1: To identify HPV vaccine text message reminder content (and  parallel - 
automated  phone  reminders) desired  by [CONTACT_315816].  
3.3.1 Population  for Objective 1 Interviews  
Target population: Families  of adolescent  girls,  clinicians,  immunization  nurses,  
administrative staff,  and school  leadership  (at the  governmental  level,  key informants  will 
include leadership  within  the KCCA and  Ministry  of Health).  
Study  population:  Families  of adolescent  girls,  clinicians,  immunization nurses,  
administrative staff,  and school  leadership  (at the  governmental  level,  key informants  will 
include leadership  within  the KCCA and  Ministry  of Health).  
Accessible population:  Families  of adolescent  girls,  clinicians,  immunization  nurses,  
administrative staff,  and school  leadership  (at the  governmental  level,  key informants  will 
include leadership  within  the KCCA and  Ministry  of Health).  
3.3.2 Selection  Criteria  for Objective 1 Interviews  
Inclusion  criteria  for interviews:  
ï‚·School -affiliated  participants  must:
oBe affiliated  one of the identified  KCCA schools  (Appendix  26)
oBe in leadership  role at school  (i.e. Senior Woman or  Head  Teacher  title)
oBe involved  in HPV -vaccination  efforts  at school
ï‚·Government -Affiliated  Participants  must:
oBe local or  national  government  official  involved  in an immunization programs
ï‚·Caregiver participants:
oIs the primary  caregiver  of adolescent  girl aged 10-[ADDRESS_388695] a phone  in the  household
oAdolescent  is willing  to take  part in interview
Page  14 of 142 ï‚·Adolescent  participants:
oIs an adolescent  girl aged 10-[ADDRESS_388696] a phone  in the  household
oCaregiver is willing  to take  part in interview
Exclusion criteria:  
ï‚·Those who are unable to consent/assent to the study
ï‚·Those unable to be interviewed at the affiliated study health centres
3.3.[ADDRESS_388697] not completed the HPV vaccine series will be given a consent form/information 
sheet by a member of our study team. Then, they will be asked if they  have any questions and if 
they are willing to participate. After being read the consent/assent form, one willing adult 
participant who is the primary caregiver of the adolescent will be asked to sign the consent and the 
10-[ADDRESS_388698] 
not completed  the HPV vaccine series  and receive  care at the study -affiliated  healthcare centres  
about  possible  participation.  If these families  are interested,  they will be asked  to travel  to their 
study -associated  healthcare centre to be  consented  and participate in the  study  interview and  
their transp ort to and from the  health  centre will  be reimbursed.  
The interviews  will be grounded  in the  general  domains of  the critical  interpretive synthesis  
framework  put forth  by [CONTACT_315817].  After  obtaining  informed  consent, interviews  will be conducted  using a  semi- 
structured  interview  guide by [CONTACT_315818]  15 of 142 interviews  with adolescent and their caregivers.  The guide was  develop ed based  on the  
investigatorsâ€™  experience  with HPV vaccination.  Audio -recorded  interviews will last 30-40 
minutes.  We will use open -ended  questions  with neutral  probes  to facilitate  discussion  and 
\encourage unbiased  responses.  In addition,  rather  than leading  the interview based  on a 
predetermined  hypothesis,  we will  allow the concepts  to emerge inductively.  
We will seek to interview 30 caregiver  and adolescent  dyads/triads,  but will use  an iterative data  
collection  and analysis  approach  and continue data collection  until data saturation  is reached  
(e.g. no new themes arise from  the data).  Eligible  criteria  are outlined  as above. Adults  and 
adolescents  will be interviewed  concurrently,  but separately  to facilitate comfort  and encourage  
honest  answers.  Family  interviews  will concentrate on text message reminder content,  focusing  
on the  attitudes,  perceived  norms  and perceived  control that may affect  intent  to vaccinate in the  
Phillips et al model.  We will also assess  desired  message timing  and phrasing.  Additionally,  we 
will assess  if families  want for only the caregiver  or the caregiver plus adolescent  to receive the 
messages.  
At the health  centres/clinics,  we will  interview clinicians  caring  for 10-14 year olds,  
immunization nurses,  administrative staff,  and medical  leadership  (n=12).  We will purposefully  
sample schools  from  the list of  KCCA health  centre -affiliated  schools  included in Appendix  26, 
focusing  on two per division each of which represent  a different  student  demographic  
composition.  At the study -affiliated  schools, we will interview up to two people per school  
including  the headmasters  and staff involved  in Child Days  Plus/HPV vaccination.  Interviews  
will include content  discussions  regarding  experiences  with familiesâ€™ vaccine  knowledge  and 
attitudes  as well as community  access  and facility  readiness  factors  from  the Phillips et al model  
in order to align  reminder content  and timing  with current  processes.  Interviews  will take place  
in person  at the facilities  in which  the participant  works,  or another  decided upon location.  
In addition,  local  and national government  officials,  including  KCCA and  MOH leadership  
involved  in immunization  programs,  will also be interviewed  with focus on  access  and readiness  
from  the Phillips et al model  and an eye towards  sustainability  (n=4).  Interviews  will take place  in 
the leadership  offices  after written  informed  consent is obtained.  We will interview the KCCA  
Directors  of Education and Social  Services,  and of Public  Health  and Environment  as well as the 
Page  16 of 142 City Manager  of Epi[INVESTIGATOR_315784].  These individuals  together oversee vaccination  
at the KCCA - affiliated  schools,  health  centres,  and immunization posts  and in Kampala overall.  
At the MOH,  we will  interview the Program  Manager of UNEPI.  
During  the process  of data collection,  COVID -19 risk management  procedure  (Appendix  24) 
will be followed  to protect  the health  and safety  of study  participants  and researchers.  
3.3.[ADDRESS_388699]  methods  of qualitative  analysis.  Analyses  will follow  a 
systematic,  iterative  process  in which  transcripts  will be independently  read for familiarity  with 
content.  General  thematic  domains  and codes  will be identified,  and then transcripts  will be 
systematically  and independently  coded  line-by-line by [CONTACT_315819].  The coding  scheme  
will remain  flexible  and open  to accommodate  expansion  as the teams  agree  on new codes.  Double  
coding  of all data will occur  to facilitate  reliability.  Coding  inconsistencies  will be reviewed  and 
resolved  during  meetings  with the research  team.  Thematic  analyses  will then be conducted  on the 
data to identify  emerging  themes.  Qualitative  data coding  and analysis  will be facilitated  by [CONTACT_315820].  Summaries  of coded  texts  and comparative  analyses  will be discussed  with 
the investigatory  team  who were  not involved  with the coding,  as well as outside  experts,  to obtain  
validation.  The themes  identified  through  the qualitative  analysis  will be used to guide  the 
construction  of the text (and parallel  phone)  messages  that will be pre-tested  in Objective 2. 
3.4 Objective  
ï‚·Objective 2a: To develop HPV vaccine  reminders  with caregivers  and their adolescent  girls
in Kampala.
ï‚·Objective 2b: To pretest  HPV vaccine  reminders  with caregivers  and their adolescent  girls
in Kampala.
Page  17 of 142 3.4.1 Study  procedure for Objective 2a message  development  
We will design  the reminders  using  the information  gathered  under  Objective  1 to ident ify the 
themes,  content,  timing  and framing  of the SMS  reminders.  We will also use content  gathered  
during  our previous  studies  described  above,  the relevant  literature,  and the teamâ€™s  expertise  in 
text messaging,  HPV  vaccination,  adolescent  medicine,  health  literacy  and community  
engagement.  The same  message  content  and timing  will be used for those  opting  for voice  
reminders.  The messaging  will be behaviorally -informed  with the framing  based  on findings  from  
participants  from  Objective  1. Possible  examples  include  â€œloss -frameâ€  messages  that focus  on the  
negative  consequences  of an adolescent  not being  vaccinated,  and/or  â€œgain -frameâ€  messages  that 
focus  on what  can be achieved  through  vaccination.  Messages  may also include  social  comparisons  
that capi[INVESTIGATOR_315785],  contigent  on if this 
is found  to be motivating  to families  based  on the Objective  [ADDRESS_388700]  coordinator  will then design  the 
messages.  The team  will then iteratively  revise  the messages,  keepi[INVESTIGATOR_315786] 160- 
character  count  and paying  attention  to reading  level,  as assessed  by [CONTACT_315821] â€“Kincaid  readability  
test. The final draft messages  will first be designed  in English  then will be forward  translated  from  
English  into Luganda  by [CONTACT_315822] a 
second  independent  professional  translator  from  Luganda  into English.  All the while,  translators  
will ensure  proper  linguistic  and cultural  equivalence,  following  procedures  adapted  from  
guidelines  for translating  health  services  research  measure.  The two versions,  the original  English  
and the reverse -translated  English,  will then be compared  by [CONTACT_2362].  
3.4.[ADDRESS_388701]  
Target population: Families  at the adolescent  clinics, KCCA health  centres,  immunization  
posts, and families  of children  registered  at the affiliated  schools.  
Study  population:  Families  at the adolescent  clinics,  KCCA health  centres,  immuni zation  
posts, and families  of children  registered  at the affiliated  schools.  
Page  18 of 142 Accessible population:  Families  at the adolescent clinics,  KCCA health  centres,  
immunization posts,  and families  of children  registered  at the affiliated  schools.  
3.4.[ADDRESS_388702]:  
ï‚·Caregiver participants:
oIs the primary  caregiver  of adolescent  girl aged 10-[ADDRESS_388703] a phone  in the  household
ï‚·Adolescent  participants:
oIs an adolescent  girl aged 10-[ADDRESS_388704]
Exclusion criteria  
ï‚·Those who are unable to consent to the study
ï‚·Those unable to be interviewed at the affiliated study health centres
ï‚·Participation in Objective 1 study activities
3.4.4 Study  procedure for Objective 2b message  pretesting  
We will show/read  the designed  messages  with caregivers  and adolescent  to identify issues  with 
clarity  and persuasiveness.  Using  methods  previously utilized  by [CONTACT_315823],  the 
project  coordinator  will purposefully  sample  families  meeting  criteria  a above  from  the waiting  
rooms  at the adolescent  clinic  and KCCA  health  centres.  Families  will be consented/assented  as 
outlined  in objective  1. After  obtaining  informed  consent,  the project  coordinator  will share  the 
proposed  messages  and ask the caregiver  to relay  back,  in their own words,  what  the message  
means  to them  in order  to assess  clarity.  S/he will then ask families  about  the level  of 
persuasiveness  as well as any problems  or suggested  changes.  Messages  will be updated  in an 
Page  19 of 142 iterative  process  until no new message  changes  are made.  Based  on our previous  work,  we 
anticipate needing  20 dyads (with  representation  by [CONTACT_315824]).  
3.4.5 Data  management and analysis  
Final  messages  will be reverse translated  from  Luganda and  team members  will review to make  
sure that  the content  is the  same between  the messages  in the  two languages. We  will also map 
the final messages  back to the factors  of the critical  interpretive synthesis  framework  related  to 
attitudes,  perceived  norms and perceived  control,  as well as access . 
3.5 AIM 3:  To pi[INVESTIGATOR_315787]  
3.5.1 Population  
Target population:  Families of adolescent girls who visited  any of the following health 
centers: Kisenyi HC IV, Kiswa HC III, or Kawaala HC III.  
Study population:  Families of adolescent girls who visited  any of the following health centers: 
Kisenyi HC IV, Kiswa HC III, or Kawaala HC III.  
Accessible population:  Families of adolescent girls who visited  any of the following health 
centers: Kisenyi HC IV, Kiswa HC III, or Kawaala HC III.  
3.5.[ADDRESS_388705]:  
ï‚·Be an adult parent of an adolescent girl aged 10 -14 years
ï‚·Reside in Kampala and/or the surrounding districts
ï‚·Be affiliated with the study sites (care or school)
ï‚·Speak English or Luganda
ï‚·Have a cell phone with text messaging capability
ï‚·Must have ability to consent.
Exclusion Criteria:  
ï‚·Parenting adult speaks other language than English or Luganda only
ï‚·Parenting adult already enrolled in the study for another child
ï‚·Participation in Objective 1, 2a/2b study activities
3.5.3 Study procedure  
We will recruit eligible participants from the sites outlined in Aim 1 and 2. This includes health 
centres  overseen by [CONTACT_315814][INVESTIGATOR_315788] (KCCA), as well as the associated schools 
and immunization posts in the community. In addition, we will also recruit at the 
Page  20 of 142 Makerere/Mulago/Columbia Adolescent Health Clinic at Mulago National Referral Hospi[INVESTIGATOR_307], the 
teaching hospi[INVESTIGATOR_315789].  
For those vaccinated through clinic sites:  Families will be recruited multiple ways. First, families 
who are interested can enroll directly at the health centre at the times research staff are on -site, 
possibly  at the time they are being evaluated for another health condition and are not receiving the 
vaccine that day. Second, if research staff are not on -site, providers and nursing staff at the study 
sites will ask families permission to provide the research st aff with their contact [CONTACT_315825].  
For those vaccinated through community immunization posts:  Village health workers who already 
work in each vil lage will be mobilized to approach households with 10 -14 year olds who are in 
need of vaccination (have not yet been vaccinated or who have initiated but have not completed the 
series) to identify those who would be interested in the study. Research staff will contact [CONTACT_315826], as above. The use of village health workers has been previously successful for both 
immunization campaigns and other research studies.  
For those vaccinated through the Child Days Plus:  Girls will be given an information sheet and the 
study contact [CONTACT_315827]. We would get permission from the schools to 
call families back as above.  
We will enroll only one child per family; if more than one is eligible, one wi ll be randomly 
selected.  For the pi[INVESTIGATOR_86234], we will enroll families of girls who are in need of either the 
first or second dose, with an outcome of receipt of next needed dose. Due to the need to complete 
the pi[INVESTIGATOR_315790],  we will only enroll those in need of the second dose if their next 
dose is due strictly between [ADDRESS_388706] coordinator will randomize families into intervention vs. 
usual care arms (1:1 ratio) stratified by [CONTACT_315828], parental language (English or Luganda), 
and dose due (1st or 2nd) using a randomization module. Research staff will not know the study 
assignment during enrollment. The outcome assessor and analyst will remain blinded to arm 
assignments.  
Families who report on the demographic survey their highest degree of schooling as P7 or below 
will be asked at enrollment if, in the case they are randomized to the intervention, they would 
prefer a voice reminder in lieu of texts; such reminders would in clude the same content, timing and 
interactivity as the texts. While in Kampala only 2.1% of women and 0.5% of men have no formal 
education, 17.6% of women and 17.1% of men completed only some primary school.[ADDRESS_388707] the timing used for those not at boarding school. If the special timing 
is selected, we will account for the minimal interval between doses (for those in need of a second 
dose). Intervention -arm families enrolled through Child Days Plus will be sen t their series prior to 
the next Child Days Plus event at their childâ€™s school or before any other special immunization day 
events, if the school holds one.  
Intervention, Text Message Target, Content and Frequency:  
For those families randomized to the int ervention arm: Based on our previous studies as well as 
the full country HPV vaccine evaluation highlighting the parents involvement as vaccine decision 
makers, we plan for the messages to be targeted to the parent, unless in Aim [ADDRESS_388708] that 
girls should also  receive the message. All text messages are automated and will be sent in English 
or Luganda based on parental preference.  
The message sequence consists of 5 weekly, main message reminders beginning 5 weeks before the 
3DJHRI+39YDFFLQHGRVHGXHGDWHIROORZHG E\DVHULHVRISULPDU\ER RVWHUPHVVDJHV)LJXUH7KLVLV
EDVHGRQRXUSUHYLRXVVWXGLHVWKDWVKRZHGWKDWWKHPHGLDQQXPEH URIPHVVDJHVQHHGHGWRFRPHLQ
IRUDYDFFLQHZDV,IHQUROOPHQWKDSSHQVPRUHWKDQZHHNVEH IRUHWKHPDLQPHVVDJHVDUHGXHWR
VWDUWHQJDJHPHQW
PHVVDJHVZLOOEHVHQWPRQWKO\XQWLOPDLQPHVVDJHVVWDUW7KHGXHGDWHIRUWKHYDFFLQHZLOOGHSHQGRQZKHWKHUWKHILUVWLQLWLDWLRQRUVHFRQG
FRPSOHWLRQGRVHLVGXHDQGWKHHQUROOPHQWVLWH 
)RUWKRVHZKRQHHGWRLQLWLDWHYDFFLQDWLRQDQGDUH
x5HFUXLWHGDVSDUWRIWKHVFKRROEDVHGSURJUDP WKHGXHGDWHZLOOEHGHILQHGDVWKHQH[W&KLOG
'D\V3OXV
x5HFUXLWHGLQKHDOWKFHQWUHDQGQRWLQERDUGLQJVFKRRO WKHGXHGDWHZLOOEHGHILQHGDVZHHNV
DIWHUPHVVDJHLQLWLDWLRQ
x5HFUXLWHGLQKHDOWKFHQWUHDQGDUHLQERDUGLQJVFKRROV WKHGXHGDWHZLOOEHWKHQH[WVFKRRO
EUHDN
x5HFUXLWHGLQWKHFRPPXQLW\ WKHGXHGDWHZLOOEHGHILQHGD VWKHQH[W+39YDFFLQDWLRQGD\ DWWKH
FRPPXQLW\LPPXQL]DWLRQSRVWWKDWLVDWOHDVWZHHNVDIWHUPHVV DJHLQLWLDWLRQ
)RUWKRVHZKRQHHGWRFRPSOHWHWKH YDFFLQDWLRQVHULHVDQGDUH
x5HFUXLWHGDVSDUWRIWKHVFKRROEDVHGSURJUDP WKHGXHGDWHZLOOEHGHILQHGDVWKHQH[W&KLOG
'D\V3OXV
x5HFUXLWHGLQKHDOWKFHQWUHDQGQRWLQERDUGLQJVFKRRO WKHGXHGDWHZLOOEHGHILQHGDVPRQWKV
DIWHUWKHGDWHRIWKHILUVWGRVHZKLFKLVWKHUHFRPPHQGHGLQWH UYDOEHWZHHQGRVHV
x5HFUXLWHGLQKHDOWKFHQWUHDQGDUHLQERDUGLQJVFKRROV WKHGXHGDWHZLOOEHWKHQH[WVFKRRO
EUHDNWKDWLVDOHDVWPRQWKVDIWHUWKHGDWHRIWKHILUVWGRVH ZKLFKLVWKHPLQLPDODOORZHG
LQWHUYDOEHWZHHQGRVHV
x5HFUXLWHGLQWKHFRPPXQLW\ WKHGXHGDWHZLOOEHGHILQHGD VWKHQH[W+39YDFFLQDWLRQGD\ DWWKH
FRPPXQLW\LPPXQL]DWLRQSRVW WKDWLVDWOHDVWPRQWKVDIWHUWKH GDWHRIWKHILUVWGRVH
0HVVDJHVZLOOIRFXVRQZKHQZKHUHWRJRIRUWKHQH[WGRVHDQG ZLOOLQFOXGHHGXFDWLRQDO
LQIRUPDWLRQLGHQWLILHGLQ$LP 0HVVDJHVZLOOEHGLIIHUHQWIRU WKRVHZKRQHHGWKHILUVWGRVH
LQLWLDWLRQDQG
QGGRVHFRPSOHWLRQ:HZLOODOVRLQFO XGHDQLQWHUDFWLYHWH[WPH VVDJHDOORZLQJ
SDUWLFLSDQWVWRDVNIRUDQGUHFHLYHPRUHLQIRUPDWLRQDFFRUGLQJ WRWKHLUVSHFLILFQHHGVDQGUHFHLYH
DQDXWRPDWHGUHVSRQVHZLWKLQIRUPDWLRQRQWKDWVXEMHFW)RUWKR VHVWLOOXQYDFFLQDWHGERRVWHU

SEARCH Protocol June [ADDRESS_388709] data; we will stop messages for tho se already vaccinated. HPV registers for schools are 
generally kept with the affiliated KCCA health centre immunization nurses. For families of those 
unvaccinated who were first vaccinated at Child Days Plus will receive booster messages directing 
them to bring their daughter to the KCCA health centre affiliated with their school (who conducts 
their Child Days Plus outreach) as they will have missed the school vaccination day.  
Usual Care arm: Families randomized to the usual care arm  will not receive text m essage vaccine 
reminders.  
3.5.[ADDRESS_388710] a hazards ratio of 1.67 with 80% power, allowing for a 5% type I error comparing time to 
next dose.  
At the study sites,  we expect there to be, on average, [ADDRESS_388711] 913 families to meet age, language and cell phone/texting 
inclusion criteria. To meet our minimal sample size of 154 (77/arm) for this pi[INVESTIGATOR_2268]/feasibility study, 
we need to recruit 16.9% of eligible families, which is feasible. If recruitment is slower than 
expected, we wil l be able to use more KCCA sites.  
Data Management  
Vaccination data will be abstracted from the HPV vaccination registers in use clinically at the sites. 
Girls generally seek care from one site. All data will be entered into a REDCap database hosted at 
Columbia with secure access provided only to Columbia and Ugandan study staff. The Ugandan -
based project coordinator will monitor text messages sent, replies, and â€œundeliverableâ€ messages 
under the supervision of Drs. Bakeera -Kitaka and Stockwell. Linkages be tween parentsâ€™ and girlsâ€™ 
information, survey data and vaccine records will be maintained in separate password protected 
files. All final datasets will be coded.  
D10. Analytic Plan   
The primary analytic plan for the pi[INVESTIGATOR_315791] 2021 Page 24  of 142 intervention using a RE -AIM implementation framework (Reach, Effectiveness, Adoption, 
Implementation, Maintenance). We will focus only on reach, effectiveness, and implementation 
(not adoption or maintenance which is not applicable for th is pi[INVESTIGATOR_2268] ). 
Reach: We will collect data on number of families  
ï‚·approached
ï‚·eligible and ineligible (including reasons for ineligibility)
ï‚·eligible who enrolled
ï‚·number enrolled in text message vs. phone reminders
Effectiveness: While the focus of the pi[INVESTIGATOR_315792], we will also assess the effect size of the 
intervention. The outcome will be timeliness of vaccination (time to event). Time will be from start 
of main message series to receipt of the next needed dose. Data analysis will be performed using  
Stata. The primary analysis will be intention -to-treat (ITT), whether or not further messages were 
declined or undeliverable. A secondary per protocol analysis will only include those who received 
the entire set of reminders. Timeliness of vaccine receipt  will be compared using Kaplan -Meier 
curves using a stratified log rank test. In addition, in order to gain effect sizes needed for a future 
large -scale intervention, comparisons will also be stratified assessing those due for the first dose 
(initiation) a nd second dose (completion).  
Implementation: We will assess various process measures, including:  
ï‚·Messages sent/delivered (if a text message is electronically returned as undeliverable, we
will contact [CONTACT_315829])
ï‚·Number who opted out of further messages
ï‚·Number who responded to messages
ï‚·Topi[INVESTIGATOR_315793]
ï‚·Factors associated with response and drop out
ochild characteristics (age, site, school status (in or out of school), grade, relationship
with caregiver)
ofamily characteristics (age, education, employment, income, marital status, distance to
health facility, language)
We will also randomly select [ADDRESS_388712] them complete two implementation measures: Acceptability of 
Intervention Measure (AIM), Intervention Appropriateness Measure (IAM).  These were developed 
and psychometrically assessed by [CONTACT_315830] . In addition, they will also complete an adapted Health 
Information Technology (IT) Usability Evaluation Scale (Health -ITUES) .  
We will then present findings to key non -parental stakeholders (as identified under Aim 1) and 
conduct semi -structured interviews to gather feedback. Conduction of the interviews and the 
analytic plan will follow the methods outlined in Aim 1.  
3.[ADDRESS_388713] operating procedures and study risk 
management procedures.  
3.7 Ethical considerations  
Permission to carry out the study was already obtained Columbia University IRB in [LOCATION_001] City 
under expedited review for meeting the following two c riteria  
a) Research involving materials (data, documents, records, or specimens) that have been
collected, or will be collected solely for non -research purposes (such as medical treatment or 
diagnoses).  
b) Research on individual or group characteristics o r behavior or research employing survey,
interview, oral history, focus group, program evaluation, human factors evaluation, or quality 
assurance methodology.  
We sought approval for the study through the IRB at Columbia University as part of our research 
team is located within that institution. We are seeking approval through SOMREC as the other 
researchers and research participants are located in Kampala, Uganda.    
Page  26 of 142 3.8 Dissemination  
The findings  of this study  shall be availed  to the  Kampala Capi[INVESTIGATOR_315782],  the Columbia  
Department  of Pediatrics  and Child Health,  and all other stakeholders.  
Risks  / Benefits  to Subjects  
This is a minimal  risk study.  Some  caregivers  might find there are interview questions  they do 
not want  to answer;  they can skip any questions  they like and can stop the  interview at  any time.  
Interviews  can be  converted  to be  conducted  online  to decrease  risk of COVID -19 transmission  
if necessary.  Patients  do not receive  any care as part of  the study  they or their 
parent/caergiver only receive a text message.  They  can choose to act or not act on the  message.  
The vaccination  is not directly  part of  the intervention. Some  parents  might  find the alerts  to be  
intrusive,  but we will  design  them  based  on parental input.  In addition,  they can opt out at any 
time.  There is also a minimal  risk of loss of  confidentiality.  However,  we will assure  
confidentiality  as below.  
Compensation  
Staff,  caregivers,  and adolescents  taking  part in interviews  will receive Ugandan Shillings  (UgX)  
30,000 which  is equivalent  to ~USD$8,  officials  taking  part in interviews  will receive UgX  
75,000 which  is equivalent  to ~USD$18.  Families  who were contact[CONTACT_315831] -affiliated  health centre to be  consented  and participate in 
interviews  will be given  travel  compensation  of UgX 10,000 which is the  equivalent  of ~USD$3.  
Those enrolling  in the  pi[INVESTIGATOR_315794]  (UgX) 15,000 which  is 
equivalent  to ~USD$4.   These compensation  amounts  were determined  by [CONTACT_315832].  
Informed  Consent  
Page  [ADDRESS_388714]  names  will be recorded  (last names  
will be used when  it would be  culturally  or otherwise inappropriate  for an  interviewer to address  
an interviewee by [CONTACT_315833]).  Data  will be stored  on an encrypted  computers  and/or servers  
and in locked  research  offices  at Makerere University  and/or Global  Health  Uganda (the  
subcontractor).  Only  Columbia  and Ugandan  research  staff will have access to the  recordings.  
The researchers  will be responsible  for ensuring  that the  confidentiality  of the data is maintained  
at all times.  Paper documents will be stored  in a locked  cabinet  at Makerere  University  and/or  
Global  Health  Uganda.  The study  database  will reside  at Columbia  on the  RedCap  server.  The 
recordings  will be used solely  for research  purposes to inform  the content  of the intervention  and 
possible  future publications. The recordings  will be destroyed  upon  conclusion of  the study.  
Conflict of Interest  
There  are no conflicts  of interests  amongst  any of the researchers  
Collaborative Agreements  
None  
Intended  Use of Results  
The intended  use of the results is to design  a trial of text message vaccine  reminders,  which  if 
successful  could  lead to a  larger-scale text message reminder program  on timely  human  
papi[INVESTIGATOR_28597]  (HPV) vaccination  in Ugandan  adolescents.  In addition,  we will potentially  
publish a  manuscript  related  to this data.  The data  will be used for future  grant  applications . 
Storage of and access  to research  data by [CONTACT_315834] [INVESTIGATOR_25653] [ADDRESS_388715] a de -identified copy  of the final analytic trial dataset.  In addition, we will 
permit access to the data on the basis of the experience and scientific qualifications of the investigator(s) 
and their agreement to not reproduce or share the data with others and to not attempt to determine the 
identities of patients or locations. Requests must be submitted in writing on the letterhead of the 
sponsoring institution at which the research will be conducted and include identifying information about 
the Principal Investigator [INVESTIGATOR_7706] -investigators, including their curricula vitae or NIH biosketch. This data 
set will be free of identifiers that would permit linkages to individual research participants or specific 
practice sites. Research data will be made available only if appropriate I RB permission are obtained. Data 
Use Agreements will be executed as necessary. Data will be able to be exported to common statistical 
packages (SPSS, SAS, Stata, R) for analysis.  
Data  Safety  
This is a minimal  risk study.  Some  caregivers  might find there are interview questions  they do not 
want  to answer;  they can skip any questions  they like and can stop the  interview at  any time.  There is 
also a minimal  risk of  loss of  confidentiality.  However,  we will assure  confidentiality.  The researchers  
will be responsible  for ensuring  that the  confidentiality  of the data is maintained  at all times.  Paper 
documents will be stored  in a locked  cabinet  at Makerere  University  and/or  Global  Health  Uganda.  
The study  database  will reside  at Columbia  on a RedCap  server.  The recordings  will be used solely  for 
research  purposes to inform  the content  of the intervention  and possible  future publications. The 
recordings  will be destroyed  upon  conclusion of  the study.  
Data will be stored on an encrypted computers and/or servers and in locked research offices at Makerere 
University and/or Global Health Uganda (the subcontractor).  
Study timeline  
Study Activity  Time in Months  
1-[ADDRESS_388716] reminder messages  X 
AIM 3: Pi[INVESTIGATOR_315795]  X 
Outcome observation   X 
Process evaluation, analysis, stakeholder 
presentations, R33 transition package 
preparation, manuscript preparation  X 
Data analysis and report writing X X X 
Dissemination of results to stakeholders  X 
REFERENCES  
1. Bruni  L, Barrionuevo -Rosas  L, Albero  G, et al. ICO/IARC  Information  Centre  on HPV
and Cancer (HPV  Information  Centre).  World: Human  Papi[INVESTIGATOR_315796].  Summary  Report 2018. Accessed  on March  10, 2019.
2. PATH and  Child Health  and Development  Centre  (CHDC).  Shapi[INVESTIGATOR_007]  a Strategy  to
Introduce HPV Vaccines  in Uganda:  Formative Research  Results  from  the HPV
Vaccines:  Evidence  for Impact  Project.  Seattle:  PATH;  2009. Available at
http://www.rho.org/files/PATH_FRTS_Uganda.pdf Accessed  on November 2, 2019.
3. Gondos  A, Chokunonga  E, Brenner H,  et al. Cancer survival  in a southern  African  urban
population.  International  journal of cancer.  2004;112(5):860 -864.
4. Markowitz  LE, Dunne  EF, Saraiya  M, et al. Quadrivalent  Human  Papi[INVESTIGATOR_315797]:  Recommendations  of the Advisory  Committee on Immunization  Practices
(ACIP).  MMWR  Recommendations  and reports  : Morbidity and mortality weekly report
Recommendations  and reports. 2007;56(RR -2):1-24.
5. World Health  Organization.  Human  papi[INVESTIGATOR_28597]  (HPV).  Available  at
http://www.who.int/immunization/diseases/hpv/en/ . Accessed  on August  20, 2018.
6. Centers  for Disease Control and Prevention.  FDA  licensure of bivalent human
papi[INVESTIGATOR_315798]  (HPV2,  Cervarix) for use in females  and updated HPV
vaccination  recommendations  from  the Advisory  Committee on Immunization  Practices
(ACIP).  MMWR  Morbidity and mortality weekly report. 2010;59(20):626 -629.
7. Meites  E, Kempe A,  Markowitz  LE. Use of a 2-Dose  Schedule for Human
Papi[INVESTIGATOR_315799]  - Updated  Recommendations of  the Advisory  Committee on
Immunization  Practices.  MMWR Morbidity and mortality  weekly report.
2016;65(49):[ADDRESS_388717]  HPV  Infection  and disease in males.  The New England  journal of medicine.
2011;364(5):[ADDRESS_388718]  low grade cervical,  vulvar,  and vaginal
Page  30 of 142 intraepi[INVESTIGATOR_315800]:  randomised  controlled  trial. Bmj. 
2010;341:c3493.  
10. Kjaer SK,  Sigurdsson  K, Iversen  OE, et al. A pooled analysis  of continued  prophylactic
efficacy  of quadrivalent  human  papi[INVESTIGATOR_28597]  (Types  6/11/16/18)  vaccine  against  high- 
grade cervical  and external genital  lesions.  Cancer  prevention  research.  2009;2(10):868 -
878. 
11. Lehtinen  M, Paavonen  J, Wheeler CM, et al. Overall efficacy  of HPV -16/[ADDRESS_388719] grade 3 or greater cervical  intraepi[INVESTIGATOR_315801]:  4-year
end-of-study  analysis of  the randomised,  double -blind PATRICIA trial.  The Lancet
Oncology.  2012;13(1):89 -99.
12. Markowitz  LE, Dunne  EF, Saraiya  M, et al. Human papi[INVESTIGATOR_315802]:
recommendations  of the Advisory  Committee on Immunization  Practices  (ACIP).
MMWR Recommendations  and reports  : Morbidity and mortality weekly report
Recommendations  and reports. 2014;63(RR -05):[ADDRESS_388720]  and Effectiveness  of the Quadrivalent
Human  Papi[INVESTIGATOR_315803]:  A Systematic Review  of 10 Years  of Real-world
Experience.  Clinical  infectious  diseases  : an official  publication  of the  Infectious
Diseases  Society of America.  2016;63(4):519 -527.
14. World Health  Organization.  Uganda launches  Human Papi[INVESTIGATOR_315803].  Available
at http://www.afro.who.int/news/uganda -launches -human -papi[INVESTIGATOR_28597] -vaccine
Accessed  on June  17, 2018.
15. Mugisha E,  LaMontagne  DS, Katahoire AR,  et al. Feasibility  of delivering  HPV vaccine
to girls aged 10 to 15  years  in Uganda.  African  health sciences.  2015;15(1):[ADDRESS_388721] â€“ 2nd Nov 2017.
17. Kampala  Biostatistics  Unit.  In: District  Health  Information  System  2; 2019.
18. Owda AP,  B; Stockwell,  M; Kitaka,  S; Zalwango,  S;. A Retrospective Demographics and
Needs  Analysis  and Qualitative Assessment  of the  HPV vaccination  program  at KCCA
Youth Centres  in Kampala,  Uganda.
19. Kampala  Biostatistics  Unit.  In. : District  Health  Information  System  2; 2020.
20. PATH,  Child Health  and Development  Centre  (CHDC),  and the Uganda  National
Expanded  Program  on Immunization  (UNEPI).  HPV Vaccination  in Africa:  Lessons
Learned  From  a Pi[INVESTIGATOR_315804].  Seattle:  PATH;  2011. Available at
https://path.azureedge.net/media/documents/RH_hpv_lessons_learned_uganda.pdf .
Accessed  on November  2, 2019.
21. Gavi  Full Country  Evaluations Team.  Gavi  Full Country  Evaluations:  2017 â€“2018
Dissemination  Report,  Uganda.  Kampala,  Uganda:  IDRC;  2018.
22. LaMontagne DS,  Barge  S, Le NT, et al. Human  papi[INVESTIGATOR_315805]- and middle -income countries.  Bulletin  of
the World  Health Organization.  2011;89(11):821 -830B.
23. Turiho  AK, Okello  ES, Muhwezi  WW, Katahoire AR.  Perceptions  of human
papi[INVESTIGATOR_315806]:  a qualitative study.  BMC Res Notes.
2017;10(1):431.
Page  31 of 142 24. Kharbanda EO,  Stockwell  MS, Fox HW,  Rickert  VI. Text4Health:  a qualitative
evaluation  of parental  readiness for text message immunization reminders. Am J Public
Health.  2009;99(12):217 6-2178.
25. Briss  PA, Rodewald  LE, Hinman  AR, et al. Reviews  of evidence regarding interventions
to improve vaccination  coverage in children,  adolescents,  and adults.  The Task  Force on
Community  Preventive Services.  American  journal of preventive medicine.  2000;18([ADDRESS_388722]):[ADDRESS_388723]  of reminder -recall  interventions  on low
vaccination  coverage  in an inner -city population.  Arch  Pediatr  Adolesc Med.
2004;158(3):255 -261.
27. Irigoyen  MM, Findley  S, Wang  D, et al. Challenges  and successes  of immunization
registry  reminders  at inner -city practices.  Ambul Pediatr.  2006;6(2):[ADDRESS_388724] of  telephone  reminder/recall  on adolescent
immunization and preventive visits: results  from  a randomized  clinical  trial. Arch  Pediatr
Adolesc Med.  2006;160(2):157 -163.
29. Hambidge SJ, Davidson  AJ, Phibbs  SL, et al. Strategies  to improve immunization rates
and well-child  care in a disadvantaged  population:  a cluster randomized controlled  trial.
Arch  Pediatr  Adolesc Med. 2004;158(2):162 -169.
30. Daley  MF, Steiner  JF, Brayden  RM, Xu S, Morrison S, Kempe A.  Immunization  registry - 
based  recall  for a new vaccine.  Ambul  Pediatr. 2002;2(6):438 -443.
31. Jacobson Vann  JC, Jacobson RM, Coyne -Beasley  T, Asafu -Adjei  JK, Szilagyi  PG.
Patient  reminder and  recall interventions  to improve immunization rates.  The Cochrane
database  of systematic reviews.  2018;1:CD003941.
32. The Radicati  Group.  Forecast  number of mobile  users  worldwide  from  2019 to 2023 (in
billions).  Statista.  Available at  https://www.statista.com/statistics/218984/number -of-  
global -mobile -users -since -2010/ . Accessed  November  03, 2019.
33. Bangure D,  Chirundu  D, Gombe N,  et al. Effectiveness  of short  message  services
reminder on childhood  immunization programme  in Kadoma,  Zimbabwe  - a randomized
controlled  trial, 2013. BMC public  health.  2015;15:137.
34. Stockwell  MS, Kharbanda EO,  Martinez  RA, Vargas  CY, Vawdrey  DK, Camargo  S.
Effect  of a text messaging  intervention  on influenza  vaccination  in an urban, low-income
pediatric and  adolescent  population:  a randomiz ed controlled  trial. JAMA  : the journal of
the American  Medical  Association. 2012;307(16):1702 -1708.
35. Stockwell  MS, Kharbanda EO, Martinez  RA, et al. Text4Health:  impact  of text message
reminder -recalls  for pediatric and  adolescent  immunizations. Am J Public Health.
2012;102(2):e15 -21.
36. Stockwell  MS, Westhoff C, Kharbanda  EO, et al. Influenza vaccine text message
reminders  for urban,  low-income pregnant  women: a  randomized  controlled  trial. Am J
Public Health.  2014;[ADDRESS_388725] 1:e7-12.
37. Stockwell  MS, Hofstetter AM,  DuRivage N,  et al. Text message reminders  for second
dose of influenza vaccine: a  randomized  controlled  trial. Pediatrics.  2015;135(1):e83 -91.
38. Hofstetter AM,  DuRivage  N, Vargas  CY, et al. Text message reminders  for timely
routine MMR vaccina tion: A randomized  controlled  trial. Vaccine.  2015;33(43):5741 -
5746.  
Page  32 of 142 39. Hofstetter AM,  Vargas  CY, Camargo  S, et al. Impacting  delayed  pediatric influenza
vaccination:  a randomized controlled  trial of text message reminders.  American  journal
of preventive medicine. 2015;48(4):392 -401.
40. Kharbanda EO,  Stockwell  MS, Fox HW, Andres  R, Lara M, Rickert  VI. Text message
reminders  to promote human papi[INVESTIGATOR_315802].  Vaccine.  2011;29(14):[ADDRESS_388726]  of Text Message Reminders  On HPV
Vaccine Series  Completion,  Poster Symposium  2019 Pediatric Academic  Societies
Annual  Meeting  (Baltimore,  MD)
42. Gibson  DG, Ochieng  B, Kagucia EW, et al. Mobile  phone -delivered  reminders  and
incentives  to improve childho od immunisation  coverage  and timeliness  in Kenya  (M- 
SIMU):  a cluster randomised controlled  trial. The Lancet  Global  health.  2017;5(4):e428 -
e438.
43. Haji A, Lowther S, Ngan'ga  Z, et al. Reducing  routine  vaccination  dropout  rates:
evaluating  two interventions  in three Kenyan  districts,  2014. BMC  public  health.
2016;16:152.
44. Brown  VB, Oluwatosin  OA, Akinyemi  JO, Adeyemo  AA. Effects  of Community  Health
Nurse -Led Intervention  on Childhood Routine  Immunization  Completion  in Primary
Health  Care Centers  in Ibadan,  Nigeria.  Journal  of community health.  2016;41(2):[ADDRESS_388727]  African journal of medicine.
2015;34(1):3 -10.
46. Domek  GJ, Contreras -Roldan  IL, O'Leary  ST, et al. SMS text message reminders  to
improve infant  vaccination  coverage in Guatemala:  A pi[INVESTIGATOR_315807].
Vaccine.  2016;34(21):[ADDRESS_388728]-to-reach  areas  and urban  streets
of Bangladesh.  Vaccine.  2016;34(2):[ADDRESS_388729]  of Mobile  Phone  Text Message Reminders  on
Routine  Immunization  Uptake in Pakistan:  Randomized  Controlled  Trial.  JMIR public
health  and surveillance.  2018;4(1):e20.
49. Foss HS, Oldervoll  A, Fretheim  A, Glenton  C, Lewin  S. Communication  around  HPV
vaccination  for adolescents in low- and middle -income countries:  a systematic  scopi[INVESTIGATOR_315808].  Syst Rev. 2019;8(1):190.
50. Abdullahi  LH, Kagina  BM, Cassidy  T, Adebayo  EF, Wiysonge CS, Hussey  GD.
Knowledge,  attitudes  and practices  on adolescent  vaccination  among adolescents,  parents
and teachers  in Africa:  A systematic review.  Vaccine. 2016;34(34):3950 -3960.
51. Li Z, Li M, Patton  G, Lu C. Global  Development  Assistance for  Adolescent  Health  From
2003 to 2015. JAMA Network  Open.  2018;1(4):e181072.